To require the Administrator of the Drug Enforcement Administration to temporarily exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health emergency.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Email me when HR 11141 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 11141. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill directs the DEA Administrator to lift the reporting requirement for buprenorphine under the Suspicious Orders Report System until the opioid public health emergency ends. This change is intended to ease regulatory burdens on providers and improve patient access to the medication.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 11141
3 free questions a day, no accountSponsors
- Rep. Tonko, Paul [D-NY-20] (D) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 11141 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 11141 freeOr ask your AI assistant about HR 11141 directly:
Add to Claude, ChatGPT or Cursor